Details for Patent: 10,617,651
✉ Email this page to a colleague
Which drugs does patent 10,617,651 protect, and when does it expire?
Patent 10,617,651 protects JORNAY PM and is included in one NDA.
This patent has forty patent family members in fourteen countries.
Summary for Patent: 10,617,651
| Title: | Compositions for treatment of attention deficit hyperactivity disorder |
| Abstract: | Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period. |
| Inventor(s): | Lickrish; David (Camana Bay, KY), Zhang; Feng (Pflugerville, TX) |
| Assignee: | IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC. (Camana Bay, KY) |
| Application Number: | 16/227,932 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 10,617,651
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-001 | Aug 8, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-002 | Aug 8, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-003 | Aug 8, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-004 | Aug 8, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| Ironshore Pharms | JORNAY PM | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 209311-005 | Aug 8, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,617,651
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2012230733 | ⤷ Sign Up | |||
| Australia | 2016228307 | ⤷ Sign Up | |||
| Australia | 2018202002 | ⤷ Sign Up | |||
| Brazil | 112013024401 | ⤷ Sign Up | |||
| Canada | 2830788 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
